MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences
Abnormal protein phosphorylation is viewed as a trigger of most cancers, Alzheimer’s disease and Parkinson’s,
Purdue spinout Tymora Analytical Operations is using the analysis of protein phosphorylation as a platform for building out clinical research tools for drug discovery – and ultimately for diagnostics, said Anton Iliuk, Tymora’s chief technological officer.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“Being able to detect these modifications allows you to find the cause of disease progression, and also find the drugs to target and fix this particular protein change,” he said.
The Indiana startup’s building a source of revenue from its clinical R&D products – it sells reagents that help researchers analyze the protein phosphorylation that occurs in a number of diseases, particularly cancer. Tymora’s tools are meant to help with the drug discovery process – helping biotechs screen drugs before they hit clinical trials.
Tymora is hoping to leverage any success from its R&D tool platform into a new set of diagnostics, which examines the protein phosphorylation patterns in a wide range of disease, Iliuk said.
“For now, that’s further away,” he said. “So the focus now is research.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The startup has some SBIR funding, as well as from the NIH and NSF, and has been bringing in revenue from the clinical research kits since 2012 – but hasn’t raised any venture funding.
Here’s how it works.
